Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion

Summary

The purpose of this study is to investigate the safety and efficacy of endovascular treatment with or without preceding intravenous Tenecteplase in patients with late-window (4.5-24 hours of symptom onset) acute ischemic stroke due to middle cerebral artery (MCA) M1 or proximal M2 occlusion.

Timeline

Start

2024-01-25

Primary completion

2025-10-13

Completion

2025-10-13

Publications

• Xiong Y, Che F, Wang H, Hao M, Nguyen TN, Fisher M, Jin A, Cao Z, Wang Z, Yao X, Feng G, Xu Y, Guo S, Qin H, Huang X, Xu J, Chen Z, Yuan J, Li W, Hu W, Feng X, Zong L, Ye W, Duan C, Wang L, Wu S, Campbell BCV, Wang Y; TNK-PLUS Investigators. Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial. JAMA. 2026 Jun 2;335(21):1849-1858. doi: 10.1001/jama.2026.4292.

Drugs

Indications